Shares of Arena soar on potential for diet drug
The pharmaceutical company awaits results of an FDA panel's discussion on rival Vivus' diet drug.
Investors were sweeping up shares of Arena Pharmaceuticals (ARNA) today ahead of a U.S. Food & Drug Administration panel meeting on rival Vivus' (VVUS) diet drug Qnexa -- the first potential U.S. prescription weight-loss drug in years.
An FDA advisory panel will discuss Qnexa to determine whether its weight-loss benefits outweigh any side effects, such as cardiovascular risks, that have plagued diet drugs in the past.
FDA staffers said earlier this week that they were also concerned about potential risks for congenital defects, psychiatric problems such as depression, memory loss and other cognitive issues and increased body acids.
Shares of Vivus were halted pending the outcome of the panel, but Arena's stock surged 86 cents, or 20%, to $5.14 on optimism that Qnexa, and later its own diet drug Lorcaserin, will be approved.
"Imagine what a drug can do that doesn't have side effects and removes more weight," Leerink Swann analyst Steve Yoo told Thomson Reuters.
The FDA will weigh the panel's recommendation before making a final decision on the drugs. The FDA does not have to follow the recommendations of its panels, but it typically does.
Orexigen Therapeutics' (OREX) Contrave is a third diet drug the FDA will consider. Shares were up 20 cents, or 3.5%, to $5.75.
Arena shares also got a boost after data from a two-year clinical trial for Lorcaserin showed that users lost more weight than those taking a placebo. The results are published in the current edition of the New England Journal of Medicine.
More than two-thirds of Americans are overweight or obese. Last year, prescription and over-the-counter diet drugs brought in just $381.5 million in 2009, according to IMS Health.
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
[BRIEFING.COM] Equity indices have returned to their opening lows as most sectors continue to hover in the red. Defensively-minded groups are exerting pressure on the broader market as consumer staples and health care hold respective losses of 0.6% and 0.2%. On the cyclical side, the largest sector, technology, is lower by 0.2%.
Just reported, October wholesale inventories rose 1.4% while the Briefing.com consensus expected an increase of 0.3%. Today's report follows last month's revised ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|
LATEST MARKET DISPATCHES
- No more Dispatches; here's where to find market news
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
- Dow falls 59 as late-day gloom kills a rally
- Stocks held back by fiscal-cliff worries
- Stocks suffer worst weekly loss in 5 months
- Dow off 121 as post-election swoon continues
- Dow slumps 313 after Obama's re-election
- Dow jumps 133 as Americans head to the polls
These big 2013 winners delivered a profit windfall, but are due for a 2014 disappointment.